A prospective, double-blinded, randomized, placebo-controlled phase 1/2a study to assess safety, tolerability, systemic exposure, and preliminary efficacy of single intraarticular injections of 3 dose levels of SYN321 and placebo in patients with symptomatic knee osteoarthritis.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diclofenac-ethoxyethylamino-succinyl-hyaluronan (Primary)
Indications Osteoarthritis
Focus Adverse reactions; First in man
Sponsors Synartro

Most Recent Events

04 May 2023 New trial record
27 Apr 2023 According to a Synartro media release, company has been granted approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight